What it is
The treatments the US Food and Drug Administration has approved for internal contamination with actinides (radioactive heavy metals), pentetate calcium trisodium and pentetate zinc trisodium, must be given by intravenous injection or nebulized inhalation under medical supervision, and cover a limited range of radionuclides. HOPO 14-1 is an oral form of the chelator 3,4,3-LI(1,2-HOPO), which removed a broad range of actinides in preclinical models; the authors describe it as the first shelf-stable, broad-spectrum actinide chelator in clinical development that needs no intravenous access or trained personnel. In this phase 1 nonrandomized trial at a single US site, 42 healthy adults, 6 per dose level, each took one oral dose at one of 7 dose levels, from 100 mg to 7500 mg, with follow-up for 14 days. There were no serious adverse events or dose-limiting toxic effects. Drug-related adverse events included diarrhea (31%), vomiting (14%), headache (12%) and fatigue (7%), all mild to moderate, with gastrointestinal effects most evident at the highest doses. The drug was absorbed rapidly: median times to peak plasma concentration ranged from 0.86 to 1.90 hours across dose levels, exposure rose with dose, more than proportionally at higher doses, and it was eliminated mainly in feces, with minimal urinary excretion.
Why it matters
A chelator taken by mouth, with no IV line or trained staff, could be given at population scale in a radiological emergency, and this is its first human safety data. Single doses up to 7500 mg were given without dose-limiting toxicity or serious adverse events, and gastrointestinal tolerability, not dose-limiting toxicity, defined the practical single-dose ceiling.
Underlined numbers link to their source. Every metric and quoted figure is listed under Sources and data below.
Filed underRadioactive element chemistry and processing, Radiopharmaceutical Chemistry and Applications, Radioactive contamination and transfer